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Abstract
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a
phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with an increase in
lymphocytosis, prior to inducing objective responses in CLL patients. This characteristic activity presumably is due to
CLL cell redistribution from tissues into the blood, but the underlying mechanisms are not fully understood. We
therefore analyzed idelalisib effects on CLL cell adhesion to endothelial and bone marrow stromal cells (EC, BMSC).
We found that idelalisib inhibited CLL cell adhesion to EC and BMSC under static and shear flow conditions. TNFα-
induced VCAM-1 (CD106) expression in supporting layers increased CLL cell adhesion and accentuated the
inhibitory effect of idelalisib. Co-culture with EC and BMSC also protected CLL from undergoing apoptosis, and this
EC- and BMSC-mediated protection was antagonized by idelalisib. Furthermore, we demonstrate that CLL cell
adhesion to EC and VLA-4 (CD49d) resulted in the phosphorylation of Akt, which was sensitive to inhibition by
idelalisib. These findings demonstrate that idelalisib interferes with integrin-mediated CLL cell adhesion to EC and
BMSC, providing a novel mechanism to explain idelalisib-induced redistribution of CLL cells from tissues into the
blood.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the
expansion of monoclonal CD5+/CD23+ B lymphocytes in the
peripheral blood, bone marrow, and secondary lymphatic
tissues [1]. CLL B cells accumulate in vivo, but undergo
spontaneous apoptosis in vitro, unless they are co-cultured
with supportive stromal cells. This suggests that in vivo CLL
cells interact with accessory cells in tissue microenvironments
which provide growth- and survival-signals [2]. Previous studies
demonstrated that co-culture with different types of stromal
cells, such as monocyte-derived nurselike cells (NLC) [3], bone
marrow stromal cells (BMSC) [4,5] and endothelial cells (EC)
[6,7] promotes CLL cell survival and protects from spontaneous
or drug-induced apoptosis. It is also well recognized that CLL
cell growth occurs in characteristic lymphatic tissue areas
called proliferation centers or pseudofollicles [8], where
leukemia cell proliferation accounts for a daily turnover of up to
1 to 2% of the entire CLL cell clone [9]. Hence, based on in
vitro and in vivo studies it is now recognized that crosstalk
between CLL cells and the tissue microenvironment plays a
critical role in regard to the expansion of the CLL clone [10].
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Concurrent with these new insights into CLL disease
pathogenesis, novel kinase inhibitors interfering with the
proactive role of the microenvironment, particularly with B cell
receptor (BCR) signaling are under development in CLL, and
demonstrate encouraging clinical activity in early stage clinical
trials [11–13].
Idelalisib, previously called GS-1101 or CAL-101, is a potent
and selective inhibitor of the PI3Kδ isoform delta (PI3Kδ) [14].
Idelalisib induces apoptosis in B cell lines and primary B cells
from patients with different B-cell malignancies, including CLL
[15,16], diffuse large B-cell lymphoma [14], multiple myeloma
[17] and Hodgkin lymphoma [18]. Several lines of evidence
demonstrate that idelalisib interferes with the crosstalk between
CLL cells and their microenvironment. Idelalisib inhibits CLL
cell signaling pathways in response to CD40L, BAFF, TNF-α,
fibronectin and stromal cells [19]. Furthermore, idelalisib affects
CLL cells migration beneath BMSC, chemotaxis towards the
chemokines CXCL12 and CXCL13, and disrupts BCR signaling
and BCR-induced secretion of the CLL cell-derived
chemokines CCL3 and CCL4 [16].
Inhibition of CLL cell migration alone cannot fully explain
idelalisib-induced redistribution of CLL cell from tissues into the
blood, given that normal lymphocyte trafficking and homing
require intimate cooperation between adhesion molecules and
chemokine receptors [20]. Normal blood lymphocytes interact
transiently and reversibly with endothelial cells through
membrane receptors defined as selectins and integrins in a
process called rolling. Chemokines on the luminal endothelial
surface then activate chemokine receptors on the rolling cells,
which triggers integrin activation [20], resulting in cell arrest,
firm adhesion, and transendothelial migration into tissues,
where chemokine gradients direct lymphocyte localization and
retention [21]. VLA-4 integrin plays a critical role in leukocytes
trafficking, adhesion and survival through the binding with
VCAM-1 or fibronectin [22]. VLA-4 is variably expressed by
CLL patients and predicts disease progression. CLL patients
with higher VLA-4 expression are characterized by more rapid
disease progression when compared to patients with low
expression [23,24]. Moreover, VLA-4 expression increases the
ability of CLL cells to access protective niches [25]. Given the
critical role of integrin-mediated adhesion for normal
lymphocytes trafficking between blood and secondary lymphoid
tissues [26,27] and the important role of VLA-4 in CLL
pathogenesis, we hypothesized that idelalisib interferes with
integrin function and signaling. We therefore examined the
mechanism of idelalisib modulation of integrin-mediated CLL
cell adhesion and integrin signaling events.
Materials and Methods
CLL cell purification, reagents
Written inform consent was obtained in accordance with the
Declaration of Helsinki on protocols approved by the University
of Texas MD Anderson Cancer Center Institutional Review
Board (IRB), before peripheral blood samples were collected
from untreated CLL patients fulfilling clinical and
immunophenotypic criteria for CLL. Peripheral blood
mononuclear cells (PBMCs) were isolated by density gradient
centrifugation over Ficoll-Pacque (GE Healthcare, Waukesha,
WiWi, USA) and were used fresh or cryopreserved in fetal
bovine serum (FBS, BD Biosciences, San Diego, CA, USA)
plus 10% dimethylsulfoxide (Sigma-Aldrich, St Louis, MO,
USA). Purity of CD19+ CLL cells was assessed to be > 90% by
flow cytometry. Idelalisib was provided by Gilead Sciences
(Seattle, WA, USA), dissolved in DMSO at 10mM, and stored
at -20°C until use.
Cell culture
The murine stromal cell lines KUSA-H1 and 9-15c, both
derived from bone marrow of a C3H/He mouse, were
purchased from the RIKEN Cell Bank (Ibaraki, Japan) and
maintained in RPMI 1640 medium supplemented with 2.05 mM
L-glutamine (Hyclone, Logan, UT), 10% FBS (SACF
Biosciences) and penicillin-streptomycin (Cellgro). The human
mesenchymal cell line StromaNKtert, derived from bone
marrow and immortalized by human telomerase reverse
transcriptase (hTERT)[28] containing also exogene MFG-tst-
IRES-neo was purchased from RIKEN and maintained in
minimum essential Medium Eagle with Earl salts and L-
glutamine (α-MEM; HyClone) supplemented with 12.5% FBS
(SACF Biosciences, Lenexa, KS), 12.5% human serum
(Cellgro), 1μM hydrocortisone (Sigma-Aldrich, St. Louis, MO)
and 100μM 2-mercaptoethanol (Sigma-Aldrich). Primary
human MSCs, isolated from bone marrow of CLL patients,
were isolated and expanded as previously described [29].
Human umbilical vein endothelial cells (HUVEC, Cascade
Biologics, Portland OR) pooled from multiple donors, were
cultured in M200 PRF medium supplemented with Low Serum
Growth Supplement kit (Cascade Biologics) with a final
concentration of 2% FBS, 1μg/ml hydrocortisone, 10ng/ml
human epidermal growth factor, 3 ng/mL basic fibroblast
growth factor and 10 μg/mL heparin. The human microvascular
endothelial cell line HMEC-1 was purchased from the Centers
for Disease Control and Prevention (CDC, Atlanta, GA) and
was maintained in MCDB131 medium (Invitrogen, Carlsbad,
CA) supplemented with 15% FBS (SACF Biosciences), 10
mM/L L-glutamine (Hyclone), 10ng/mL Epidermal Growth
Factor (Becton-Dickinson) and 1μg/mL hydrocortisone (Sigma-
Aldrich). The murine vascular endothelial cell line UV-2,
transformed by ultraviolet, was purchased from RIKEN and
maintained in DMEM medium supplemented with 10% FBS
(SACF Biosciences), 2.05 mM L-glutamine (Hyclone) and
penicillin-streptomycin (Cellgro). RAMOS cells (ATCC, LGC
Standards, UK) were cultured in RPMI 1640 supplemented with
2.05 mM L- glutamine (Hyclone, Logan, UT), 10% FBS (SACF
Biosciences) and penicillin-streptomycin (Cellgro).
Static cell adhesion assay
Two different EC (HUVEC and HMEC-1) and two different
BMSC (9-15c and CLL-MSC) were seeded for 24 hours onto
24-well plate at a concentration of 0.8x105 cells/ml in the
appropriate cell culture medium and then stimulated for 24
hours with 10ng/mL TNFα (R&D Systems, Minneapolis, MN)
[30]. After 1 hour incubation at 37°C and 5% CO2 in complete
medium, CLL cells were added onto the confluent endothelial
and stromal cell layers to a final concentration of 5x106/well in
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presence or absence of 5 μM idelalisib, and the plates were
incubated at 37°C for 4 hours. After incubation the cells that
were not adhered to the EC and BMSC cell layers were
removed by washing the wells with RPMI 1640 medium. The
complete removal of non-adherent cells and the integrity of the
cell layer was assessed by phase contrast microscopy and
documented photographically. The EC and BMSC layers
containing the adherent CLL cells then were detached by
incubation for 1 minute with trypsin/EDTA solution pre-warmed
at 37°C (Invitrogen), followed by neutralization of the trypsin
with 1 ml of RPMI/10% FBS. Cells then were washed and
suspended in a final volume of 0.6 ml medium for counting by
flow cytometry (FACS Calibur, BD Biosciences) for 20 seconds
at 60μl/min in triplicates. A lymphocyte gate was set using the
different relative size and granularity (forward scatter and side
scatter) to exclude endothelial and stromal cells from the count,
as described before [31]. The number of adherent cells under
each condition was expressed as percentage of the control for
each experiment.
Parallel plate flow detachment assay
Slides were coated with HUVEC in culture media for 24
hours and then stimulated with TNFα (10ng/ml) (R&D systems)
in fresh medium for 24 hours. After 1 hour incubation in
complete medium at 37°C in 5% CO2, 5x106 CLL cells, treated
with 5μM idelalisib for 1 hour at 37°C and untreated controls,
were injected into the flow chamber and allowed to settle on
the slides for 20 minutes. For cell adhesion to VCAM-1 (R&D
Biosystems), slides were coated with 10 μg/ml VCAM-1 or
ovalbumine (Sigma-Aldrich) overnight at 4°C. The slides were
washed with PBS and blocked with 2% ovalbumine before
addition of Ramos. 5x106 Ramos cells were either treated or
not treated with 5 μM idelalisib for 1 hour at 37°C and allowed
to adhere to VCAM-1 slides for 20 minutes. Using a computer
controlled syringe pump (Harvard Apparatus Holliston, MA), an
increasing linear gradient of shear flow was applied over the
adherent cells for 300 seconds and the number of cells
remaining adhered was recorded by digital microscopy. Shear
stress calculations were determined every 50 seconds where
the shear stress in dynes/cm2 was defined as 6μQ/wh2 where μ
is the viscosity of the medium (0.007), Q is the flow rate in
cm3/s, w is the width of the chamber (0.3175 cm) and h is the
height of the chamber (0.0254 cm). All the samples were
assayed in triplicates.
VCAM-1 and VLA-4 flow-cytometry staining
HUVEC and HMEC-1 were grown in the appropriate cell
culture medium until confluence and then stimulated with TNFα
(R&D Systems) at a concentration of 10ng/ml for 24 hours and
then detached with 5mmol/L EDTA/EGTA in Dulbecco’s PBS
(HyClone), pelleted and washed with RPMI 1640 + 0.5%
bovine serum albumin (BSA). Then cells were stained with PE-
conjugated VCAM-1 antibodies (BD Biosciences) or isotype-
matched control antibodies (mouse IgG1-PE; BD Biosciences)
and incubated for 20 minutes at 4°C. VLA-4 expression in CLL
cells was detected in 10 CLL samples using anti-CD19 APC
and anti VLA-4 PE (BD Biosciences) or isotype control.
Samples were washed with FACS Buffer and resuspended in
400 μl for assessment on a FACS Calibur (BD Biosciences).
CLL viability in EC and BMSC co-cultures
For co-culture experiments two different EC (HUVEC, UV-2)
and 2 different BMSC (NKtert, KUSA-H1) were seeded the day
before the experiment onto a 24-well plate at a concentration of
5x104 cells/well and incubated at 37°C in 5% CO2 in the
corresponding medium. After confirming the confluence of the
cell layer by phase contrast microscopy, CLL cells were added
onto the cell layer at a final concentration of 2x106/ml. As
control, CLL cells were cultured in medium suspension at a
concentration of 2x106/ml. To evaluate the effect of idelalisib on
CLL cells viability, co-cultures were treated with 5μM idelalisib.
At the indicated time-points, CLL cells were collected and
tested for cell viability. Determination of CLL cell viability in the
presence or absence of idelalisib was assessed with the
analysis of mitochondrial transmembrane potential by 3,3’
dihexyloxacarbocyanine iodide (DiOC6; Molecular Probes,
Invitrogen) and cell membrane permeability to Propidium Iodide
(PI; Sigma- Aldrich)[3]. CLL cells viability was determined at
baseline and after 24, 48 and 72 hours.
Detection of phospho-proteins by flow cytometry
Phospho-protein expression in CLL cells was detected after
1 hour and 24 hours of co-culture with HMEC-1 and after 1
hour of stimulation with a monoclonal antibody for α4β1 integrin
(19H8) [32] with antibody crosslinking using F(ab’)2 fragments
of goat anti-mouse IgG (Invitrogen) in presence or absence of
5μM idelalisib. The following antibodies were used for detection
of activated phospho-proteins: anti-pAkt T308 AlexaFluor 488
(Cell Signaling Tecnology) and anti-CD19 PE-cy5 (BD
Biosciences) or an isotype-matched control antibody (rabbit
IgG-AlexaFluor 488, Cell Signaling Technology). 1x106 CLL
cells were suspended in PBS containing 4% paraformaldehyde
to block stimulation reaction. After 10 minutes incubation, cells
were washed once in cold PBS and stored overnight. Then
cells were washed and resuspended in PBS containing 1%
bovine serum albumin and incubated with antibodies for 1 hour
at room temperature. Samples were washed with PBS + 1%
BSA and resuspended in 350 μl PBS + 1% BSA for
assessment on a FACS Calibur (BD Biosciences).
Immunoblotting
CLL cells were starved in RPMI + 0.5% BSA for 2 hours at
37°C then cultured in suspension or co-cultured with HMEC-1
for 1 hour and 24 hours at 37°C. Cells were washed once with
cold PBS and lysed ice for 30 minutes with lysis buffer
containing 25 mM HEPES, 300 mM NaCl, 1.5 mM MgCl2,
0.5% sodium deoxycholate, 20 mM glycerophosohate, 1%
Triton X-100, 0.1% SDS, 0.2 mM EDTA, 0.5 mM dithiothreitol,
1 mM sodium orthovanadate, and protease inhibitor. Cells were
pelleted with centrifugation at 14.000 rpm for 15 minutes at 4°C
and supernatant was stored at -80°C. Protein content was
determined using the detergent compatible (DC) protein assay
kit, according to manufacturer’s instructions (Bio-Rad
Laboratories, Hercules, CA). Aliquots (50 µg) of total cell
protein were boiled with Laemmli sample buffer and loaded
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onto 4% to 12% SDS-polyacrylamide gradient gels and
transferred to nitrocellulose membranes (GE, Osmonics
Labstore, Minnetonka, MN). Membranes were blocked for 1
hour in PBS-Tween containing 5% nonfat dried milk and
incubated with primary antibodies either overnight or for 3
hours followed by species-specific horseradish peroxidase
(HRP)-conjugated secondary antibody (diluted 1:10000) for 1
hour. The blots were visualized by enhanced
chemiluminescence according to the manufacturer’s
instructions (Pierce Biotechnology, Rockford, IL) and
normalized to the actin levels in each extract. Membranes were
probed at 4°C with the following primary antibodies: anti-total
AKT, phospho-AKT (clones T308 and S473) (Cell Signaling,
Danvers, MA), and β-Actin (Sigma- Aldrich). Immunoreactive
bands were visualized using peroxidase-conjugated secondary
antibodies (GE Healthcare) and enhanced chemiluminescence
detection system (Pierce Biotechnology).
Data analysis and statistics
Results are shown as mean ± standard error mean (SEM) of
at least 3 experiments. Analyses were performed using
GraphPad Prism 4 Software for Macintosh (GraphPad software
Inc., La Jolla, CA, USA). Student paired or unpaired T tests
were used for statistical comparison. The Spearman test was
used for estimating correlations between quantitative
parameter. A P value ≤ 0.05 was considered statistically
significant. Flow cytometry data were analyzed using FlowJo
version 8.8.7 software (Treestar).
Results
Idelalisib inhibits CLL cell adhesion to EC and BMSC
Primary CLL cells displayed a significant increased adhesion
to both EC and BMSC stimulated with TNFα when compared to
unstimulated controls (Figure 1A). For example the mean
relative number (±SEM) of CLL cells adherent to TNFα-treated
HMEC-1 increased to 144.3% ± 8.3% (p<0.01, n=8) and to
143.9% ± 16.9% on TNFα-treated CLL-MSC respectively
(p<0.05, n=8) when compared to respective untreated controls
(Figure 1A). Next, we found that CLL cell adhesion to TNFα-
stimulated EC and BMSC was inhibited by idelalisib. The mean
relative adhesion (±SEM) of CLL cells to EC was significantly
reduced from 162.8% (±27.7%) to 95.7% (±12.1%) using
HUVEC, and from 144.3% (±8.3%) to 99.4% (±7%) using
HMEC-1 cells. CLL cell adhesion to TNFα-stimulated BMSC
was significantly reduced from 128.9% (±7.3%) to 94.1%
(±7.9%) using 9-15c cells, and from 143.9% (±16.9%) to
100.7% (±10.1%) using CLL-MSC (Figure 1A). Idelalisib also
significantly reduced CLL cell adhesion to unstimulated 9-15c
BMSC, but this idelalisib-induced reduction in adhesion of CLL
cells to other unstimulated EC or BMSC layers was minor and
did not reach statistical significance. CLL cell adhesion was
reduced by idelalisib to 91.2% (±6.8%, ns, n=8) on HMEC-1, to
87.5% (±11%, ns, n=8) on HUVEC, to 73.9% (±6.2%, p<0.01,
n=8) on 9-15c, and to 93.9% (±6.9, ns, n=8) using CLL-MSC.
Phase-contrast photomicrographs document increased
numbers of adherent CLL cells after TNFα-treatment and
reduced numbers of adherent CLL cells after treatment with
idelalisib (Figure 1B). Notably, CLL cells that adhere to TNFα-
treated cell layers appear larger in size, presumably because of
spreading during the process of adhesion, a well-recognized
process that is related to rearrangement of the cytoskeleton
[33].
Idelalisib interferes with cell adhesion to activated
endothelium and VCAM-1 under shear flow conditions
To investigate effects of idelalisib on CLL cell adhesion to EC
under conditions that mimic physiologic flow conditions within
blood vessels, we used parallel plate flow assays. CLL cells
treated with 5μM idelalisib or unstimulated control cells were
allowed to adhere to TNFα-stimulated HUVEC. As shown in
Figure 2A, TNFα treatment increased CLL cell adhesion to
HUVEC when compared with unstimulated controls. Idelalisib
effectively inhibited CLL cell adhesion to EC under shear flow
conditions at low (15 dynes/cm2) and higher shear forces (30
dynes/cm2). As illustrated in Figure 2B, the mean (±SEM)
relative number of adherent CLL cells on HUVEC increased
from 10.8 % (±2%) to 23.3 % (±2.6%) after TNFα stimulation
(p<0.01, n=5) at 15 dynes/cm2. Idelalisib decreased CLL cell
adhesion to TNFα-activated HUVEC from 23.3% (±2.6%) to
13.9% (±2.4%) at low shear force of 15 dynes/cm2 (p<0.05,
n=5). At high shear force 30 dynes/cm2 the mean (±SEM)
number of cells adherent to HUVEC increased from 4.1%
(±0.7%) to 12.9 (±1.8%) in presence of TNFα stimulation
(p<0.01, n=5) that decreased to 7.8% (±1.4%) in presence of
5μM idelalisib (p<0.05, n=5).
As previously described, treatment with TNFα induces
VCAM-1 expression on endothelial cells [34,35] and in addition,
BCR activation increases adhesion to VCAM-1 of primary cells
and B cell lines [36]. Therefore, we investigated specifically if
adhesion mediated by VCAM-1 was affected by idelalisib in a B
cell line. Ramos cells were treated and not treated with
idelalisib and allowed to adhere to slides coated with VCAM-1.
As shown in Figure 2C, idelalisib significantly inhibited Ramos
cell adhesion to VCAM-1. At a shear force of 22.5 dynes/cm2
the mean (±SEM) number of cells adherent to VCAM-1
decreased from 41.6%±5.8% to 17.7%±6.1% in presence of
idelalisib (n=3; p<0.05). Collectively, these data confirm the
earlier results in the static adhesion assays, corroborating that
idelalisib inhibits CLL cell adhesion to activated endothelium
and in particular suggest an interference with the interaction
between VLA-4 and VCAM-1.
VLA-4 expression on CLL cells and VCAM-1 on EC/
BMSC increase CLL adhesion, which is inhibited by
idelalisib
Next, we addressed the effect of increased adhesion
mediated by TNFα to more adhesive interactions between
VLA-4 on CLL cell and VCAM-1 expressed on EC and BMSC.
We analyzed VCAM-1 expression before and after TNFα
treatment on EC and BMSC and VLA-4 in CLL cells. We
confirmed that TNFα treatment strongly upregulated VCAM-1
expression on the surface of HUVEC and HMEC-1 (n=3), as
shown in Figure 3A. Moreover CLL cells showed variable
expression of VLA-4 integrin ranging from 1% to 78%, as
shown in 3 positive representative samples (cut-off of 30%) in
Idelalisib Targets Integrins
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Figure 1.  Idelalisib inhibits CLL cell adhesion to TNFα-stimulated EC and BMSC.  CLL cells were allowed to adhere to EC
(HUVEC or HMEC-1) or BMSC (9-15c or CLL-MSC). EC and BMSC were either unstimulated (control) or stimulated with TNFα
(10ng/ml). The bar diagrams represent the mean relative adhesion (±SEM; n=8) of CLL cells in the presence or absence of idelalisib
to EC and BMSC compared with the control. TNFα treatment increases the adhesion of CLL cells to EC and BMSC and in presence
of idelalisib is significantly inhibited (*p<0.05; **p<0.01). (B) Representative phase contrast photomicrographs demonstrating CLL
cell adhesion to HMEC-1 either treated or untreated (control) with TNFα. Treatment with TNFα increased the number of adherent
CLL cells to HMEC-1 in comparison to the control (on the bottom left); in presence of idelalisib the number is reduced both in
presence of TNFα treatment.
doi: 10.1371/journal.pone.0083830.g001
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Figure 2.  Adhesion to activated endothelium and VCAM-1 is inhibited by idelalisib.  A linear gradient of shear flow increasing
from 0-45 dynes/cm2 is applied over the adhered cells and the number of adherent cells is determined by the percentage of cells
remaining every 50 seconds. (A) CLL cells were either treated or not treated with idelalisib and allowed to adhere to HUVEC
stimulated or not stimulated (control) with TNFα (n=5). The data displayed the mean relative adhesion (±SEM) at different shear
forces compared with the baseline adhesion for each condition. (B) The bar diagrams display the percentage of cells adherent to
HUVEC at two representative shear forces (15 and 30 dynes/cm2). Displayed are the means (±SEM) from 5 different patients.
idelalisib significantly inhibits the adhesion of CLL cells to HUVEC TNFα stimulated at low and high shear forces (*p<0.05;
**p<0.01). (C) Ramos cells were treated or not treated with idelalisib and allowed to adhere to slides coated with VCAM-1 or
ovalbumin (control). Idelalisib is able to interfere with VCAM-1-mediated adhesion at different shear forces (n=3, *p<0.05). The data
display the mean relative adhesion (±SEM) at different shear forces compared with the baseline adhesion for each condition.
doi: 10.1371/journal.pone.0083830.g002
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Figure 3A. Given the high expression of VCAM-1 on EC/BMSC
and the variable VLA-4 expression on CLL cells, we compared
the relative adhesion of CLL cell to activate endothelium with
their individual VLA-4 expression. We observed a significant
positive correlation between VLA-4 expression (%) and
adhesion to TNFα-treated HUVEC (Figure 3B; r=0.818,
p=0.004). These data were also confirmed using mean
fluorescence intensity ratios for VLA-4 (data not shown). Next,
we investigated the ability of idelalisib to interfere with CLL
adhesion in VLA-4 high and VLA-4 low groups. The mean
relative adhesion (±SEM) of CLL cells on TNFα-treated
HUVEC layer significantly decreased from 206% (±34.2%) to
118.5% (±20.5%) (n=5, p<0.05) in VLA-4 high expression
group, and from 115.6% (±18.3) to 98.8% (±14.8%) in VLA-4
low expression group (n=5, p=ns). Using idelalisib to interfere
with VLA-4-VCAM-1 interaction, we found a strong inhibition of
CLL adhesion to TNFα-treated endothelium in VLA-4 high
expression group (40.6% inhibition of adhesion) compared with
VLA-4 low expression group (12.1% of inhibition of adhesion)
(Figure 3C, n=10, p<0.05). Collectively, our data suggest that
idelalisib significantly inhibits CLL adhesion to EC and BMSC
interfering with VLA-4 and VCAM-1 interaction.
Idelalisib inhibits CLL cell survival in EC and BMSC co-
culture
BMSC and to a lesser degree EC are recognized for their
capacity to protect CLL cells from spontaneous apoptosis in a
contact-dependent fashion. To elucidate the relative capacity of
BMSC versus EC for protecting CLL cells, we performed a
direct comparison of these different support systems and
measured effects of idelalisib in these co-cultures. While both,
EC and BMSC support the viability of CLL cells, we noted
comparably less protection from spontaneous apoptosis when
compared directly with BMSC (Figure S1 A,B). To test the
effect of idelalisib on EC- and BMSC- mediated CLL cell
protection, CLL cells were cultured on EC (HUVEC and UV-2)
or BMSC (NKtert and KUSA-H1) in presence or absence of
5μM idelalisib and CLL cell viabilities were assessed at 24, 48,
72 hours. First, we tested the effects of idelalisib on EC and
BMSC and we found no influence on viability and morphology
(data not shown). In a representative case (Figure 4A),
idelalisib reduced CLL cell viability from 51.7% to 41.9% with
HUVEC, 47.9% to 41% with UV-2, 97.5% to 64.9% with NK-tert
and 92.9% to 85.1% with KUSA-H1 after 48 hours. We also
found a significant reduction in the viability of CLL cells co-
cultured with EC and BMSC in presence of idelalisib compared
to the control at all time-points. At 24 hours, the mean relative
viability of CLL cells in presence of idelalisib was 73.9%
(±2.2%, p<0.01, n=7) with HUVEC, 81.7% (±2.5% p<0.01, n=7)
with UV-2, 63.0% (±2.4% p<0.01, n=7) with NKtert and 71.1%
(±4.1% p<0.01, n=7) with KUSA-H1 (Figure 4B). These data
demonstrate that idelalisib can overcome EC- and BMSC-
mediated CLL cell protection. In addition the impact of idelalisib
is roughly equivalent in its ability to overcome CLL B cell
protection for both cell types.
Idelalisib inhibits EC- and VLA-4-induced signaling in
CLL cells
To determine effects of idelalisib on EC-induced signaling,
we analyzed AKT phosphorylation in presence or absence of
idelalisib after co-culture with HMEC-1 by flow cytometry. Using
mean fluorescence intensity ratios (MFIR), we quantified AKT
phosphorylation and normalized for the MFIR of CLL cell
cultured alone. Overlay histograms depict relative pAKT
expression in a representative CLL sample co-cultured with
HMEC-1 for 24 hours in presence or absence of idelalisib
(Figure 5A). Figure S2A shows mean relative levels of pAKT,
measured after 1 and 24 hours of EC co-culture. While
differences after 1 hour of co-culture were small, AKT
phosphorylation was increased after 24 hours in co-culture with
HMEC-1 from 100.9% (±6.8%) to 117.2% (±7.6%) (p<0.01,
n=4). Idelalisib significantly decreased EC-induced pAKT levels
to 76.7% (±8.8%) after 24 hours (p < 0.05). We consistently
found that after 24h, CLL adhesion to EC increased the
percentage of CLL positive for AKT phosphorylation in CLL
cells from 83.5% (± 5.3%) to 88.5% (5.4%) (n=4, p<0.05) and
idelalisib decreased EC-induced AKT phosphorylation to 74.1%
(±7.8%) (n=4; p<0.05) as shown in Figure 5B. These findings
were confirmed by immunoblot analyses (Figure 5C and Figure
S2B), which confirmed an increased AKT phosphorylation
induced by CLL cell adhesion to EC and pAKT inhibition in
response to idelalisib treatment. Furthermore we investigated,
if VLA-4 activation can also induce AKT activation, therefore
we incubated CLL cells with activating anti-VLA-4 (19H8) mAbs
for 1 hour, followed by crosslinking in the presence or absence
of idelalisib. As shown in Figure 5D, AKT phosphorylation
induced by VLA-4 stimulation was able to increase AKT
phosphorylation in CLL from 69.2% (±7.4%) to 84.1% (±8.4%)
(n=5, p<0.05) and in presence of idelalisib pAKT decreased to
79.9% (±8.3%) (n=5, p<0.05). The crosslinking secondary
antibody alone did not stimulate AKT phosphorylation (data not
shown). This result was confirmed also by immunoblot with 3
different CLL samples (Figure 5D and Figure S3B). These data
demonstrate that idelalisib is able to inhibit AKT
phosphorylation induced by EC and VLA-4-triggering,
indicating that idelalisib interferes with CLL cell adhesion by
inhibition of VLA-4 integrin function and signaling.
Discussion
Currently, several inhibitors of kinases downstream of B cell
receptor are developed in clinical trials in CLL, and are
emerging as promising alternative targeted therapies for CLL
patients. These new agents include the spleen tyrosine kinase
(Syk) inhibitor fostamatinib [11], Bruton’s tyrosine kinase (BTK)
inhibitor ibrutinib (formerly PCI32765) [12], and the PI3Kδ
inhibitor idelalisib (formerly CAL-101) [16], and all have shown
similar characteristic clinical activity. Typically, these agents
cause rapid resolution of lymphadenopathy and/or
organomegaly with redistribution of CLL from tissues into the
blood, resulting in a surge in lymphocytosis during the first
weeks of therapy, which later oftentimes slowly resolves. This
characteristic activity suggests that these agents interfere with
the CLL cell adhesion and other tissue retention signals.
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Figure 3.  Idelalisib affects adhesion mediated by VLA-4 and VCAM-1 interaction.  (A) On the left, displayed are fluorescence
histograms depicting the relative fluorescence intensity of HUVEC and HMEC-1 stained with anti-VCAM-1 mAb either treated or not
treated (control) with TNFα (10ng/ml) for 24 hours. Mean fluorescence intensity ratio was calculated by dividing the mean
fluorescence intensity for VCAM-1 by the mean fluorescence of the isotype control in both conditions. On the right, representative
fluorescence histograms of CLL cells stained with anti-VLA-4 (grey histograms) or the corresponding isotype control (white
histograms). THE MFIR is displayed below the histograms. (B) A positive correlation is displayed between VLA-4 expression (%)
and the relative adhesion of CLL cells to HUVEC stimulated with TNFα (n=10). (C) The box plot displays a comparison of CLL cell
adhesion to HUVEC TNFα-stimulated in presence or absence of idelalisib in VLA-4 high (n=5) and VLA-4 low (n=5) expression
groups. Bar diagram represents the percentage of inhibition in CLL adhesion to HUVEC stimulated with TNFα induced by idelalisib
in VLA-4 high and VLA-4 low CLL samples relative to adhesion observed without idelalisib. Data are shown as mean ±SEM
(*p<0.05).
doi: 10.1371/journal.pone.0083830.g003
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Figure 4.  Idelalisib overcomes endothelial cells and bone marrow stromal cells mediated CLL cell protection.  (A) CLL cells
were co-cultured with HUVEC, UV-2, NKtert and KUSA-H1 in presence or absence of 5μM idelalisib. The gates in the contour plots
exemplify viable CLL cells in one representative sample. (B) The bar diagrams represent the mean relative viabilities of CLL cells
co-cultured in normal conditions (control) or in presence of 5μM idelalisib with EC and BMSC. Viabilities in idelalisib-treated samples
were normalized to the corresponding viabilities of control samples at the respective time-point (100%) to account for differences in
spontaneous apoptosis. Displayed is mean±SEM from 7 different samples (*p<0.05; **p<0.01).
doi: 10.1371/journal.pone.0083830.g004
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Figure 5.  Idelalisib down-regulates integrin-induced AKT phosphorylation.  (A) Overlay histograms depict the mean AKT
phosphorylation (pAKT) fluorescence intensity of CD19+ CLL cells in a representative case. The solid grey histogram depicts pAKT
staining of CLL cells in co-culture with HMEC-1 without idelalisib and the black line histogram depicts of CLL cells in co-culture with
HMEC-1 in presence of 5 μM idelalisib. AKT phosphorylation was analyzed in CLL cells after 1 hour and 24 hours of co-culture with
HMEC-1 either in presence or absence of idelalisib. pAKT was evaluated by flow cytometry in CD19+ CLL cells gated from 4
different patients. (B) CLL cells were cultured in medium alone and in co-culture with HMEC-1, either in presence or absence of
idelalisib for 1 hour or 24 hours. The bar diagrams represent the mean ± SEM of pAKT positive cells (%) (n=4, p<0.05). (C)
Displayed are immunoblots from 3 representative CLL cell samples cultured alone or in co-cultured with HMEC-1 in presence or
absence of idelalisib for 24 hours. Lysates were probed with antibodies to pAKT (S473) and actin. (D) CLL cells were stimulated or
no stimulated with anti-VLA4 mAbs (clone 19H8) in the presence or absence of idelalisib. Displayed are the means ± SEM from 5
different patients (*p<0.05). The immunoblots on the right hand side depict AKT activation in 3 representative CLL samples
stimulated with anti-VLA4 in presence or absence of idelalisib.
doi: 10.1371/journal.pone.0083830.g005
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Our previous works on idelalisib [16], ibrutinib [37], and R406
[38] suggest that disruption of chemokine receptor signaling
and function by these inhibitors is involved in the CLL cell
redistribution phenomenon. Mechanistically, this concept,
which is largely based on chemotaxis assays and signaling
studies, likely does not fully explain the clinical findings given
the plethora of means by which CLL B cells can adhere to
stromal cells. To better characterize and understand the nature
of the idelalisib-induced CLL cell redistribution, we explored the
effects of idelalisib on CLL cell adhesion to different stromal
cell types present in the CLL microenvironment (BMSC, EC). In
our in vitro models, we analyzed CLL cell adhesion under static
and shear flow conditions. Our results confirmed that
interactions between VLA-4 (CD49d) on CLL cells and VCAM-1
(CD106) on the stromal cell surface play an important role in
CLL cell adhesion to stromal cells [39]. Treatment of EC and
BMSC with TNFα strongly increased VCAM-1 expression on
the stromal cells that facilitated adhesion of CLL cells via
VLA-4 expression. Our data demonstrate that idelalisib affects
CLL adhesion to both, EC and BMSCs, which is more
pronounced in CLL cells with higher VLA-4 expression,
corroborating the importance of VLA-4 and VCAM-1 in CLL cell
adhesion. Interestingly, and along the same lines, de Rooij and
colleagues recently reported that the BTK inhibitor ibrutinib
strongly inhibits VLA4 integrin-mediated adhesion of lymphoma
cell lines and primary CLL cells to fibronectin and VCAM-1, and
proposed this activity, along with inhibition of chemokine
receptor function, as an underlying mechanism to explain the
CLL cell redistribution caused by this BTK inhibitor [40]. Our
data corroborate this concept and extend de Rooij’s findings in
our CLL co-culture systems with both BMSC and EC. This is of
relevance to the in vivo situation in that these cells will more
closely resemble the in vivo microenvironment. In this scenario,
CLL cells enter and accumulate into lymph nodes where
adhere to accessory cells using different integrins and in
particular VLA-4. This induces an increase in lymph nodes size
supported by different growth and survival signals. Idelalisib is
able to interfere with integrin-mediated adhesion, in particular
with VLA-4 on CLL cells and VCAM-1 on EC/BMSC, causing
lymph node shrinkage with a redistribution of CLL into the
blood.
Besides tissue homing and retention, increased CLL cell
survival is an expected consequence of adhesion to stromal
cells, but effects of idelalisib on EC- and BMSC-mediated CLL
cell survival have not previously been studied in detail. The
novel findings in this study are the characterization of idelalisib
effects on CLL cell adhesion to BMSC and EC under static and
shear flow conditions, its effects on CLL cell viability in side-by-
side co-cultures with BMSC and EC, and the role of the VLA-4-
VCAM-1 axis in AKT pathway activation in CLL. More
specifically, we found that BMSC were consistently more
effective in maintaining CLL cell viability when compared with
EC. The exact mechanism for this is unclear but seems not too
surprising given that BMSC are critical and more numerous
components of the supporting cellular infrastructure for
hematopoietic cells in the marrow microenvironment. The
finding that idelalisib can significantly interfere with these pro-
survival effects implies that the adhesive interaction, and not
exclusively BCR activation and signaling, contributes to CLL
cell activation and survival in the tissue sites. Another new
finding in this study is related to the specific stimulation of
VLA-4 integrins on CLL cells causing increased the activation
of the pro-survival AKT pathway in the process of CLL
adhesion to EC or BMSC. Idelalisib inhibited AKT pathway
activation, although to variable degrees in different patient
samples, supporting a role of PI3Kδ in integrin signaling.
In conclusion, our study demonstrates that idelalisib
interferes with CLL cell adhesion to different cells present the
tissue microenvironment by inhibiting interactions between
VLA-4 on CLL cells and VCAM-1 on stromal and endothelial
cells. Idelalisib not only disrupts CLL cells adhesion, but also
thwarts pro-survival pathways activated during CLL cell
adhesion. These data provide novel insight into the mechanism
of action of idelalisib that relate to the redistribution of CLL cells
during idelalisib therapy.
Supporting Information
Figure S1.  (A) CLL cells were cultured in medium alone, in
co-culture with two EC (HUVEC and UV-2) and in co-
culture with two BMSC (NKtert and KUSA-H1) for three
different time-points: 24, 48, 72 hours. Contour plots display
a representative CLL sample viability after 48 hours. The gates
represent the viable cells positive to DiOC6 and negative to PI.
(B) The line graph displays mean±SEM CLL viabilities from 7
different patients after 24, 48, 72 hours of culture. Both EC and
BMSC significantly support CLL viability at different time-points
(*p<0.05; **p<0.01) compared to CLL culture in medium alone.
(DOC)
Figure S2.  (A) The bar diagrams represent the mean
fluorescence intensity ratio (MFIR) for AKT
phosphorylation in CLL cells co-cultured with HMEC-1,
either treated or no treated with idelalisib, normalized for
the MFIR of CLL cultured alone (control). MFIR was
calculated by dividing the mean fluorescence intensity for pAKT
by the mean fluorescence of the respective isotype control. (B)
Displayed are immunoblots from 2 representative CLL samples
of 4 patients co-cultured with HMEC-1 in presence or absence
of idelalisib for 24 hours. Lysates were probed with antibodies
to pAKT (Tyr 308) and actin.
(DOC)
Figure S3.  A) The bar diagrams represent the mean
relative fluorescence intensity ratio of CLL cells stimulated
with 19H8 mAb (VLA-4) either in presence or absence of
idelalisib. Mean fluorescence intensity ratio were normalized
for the corresponding MFIR at baseline. Displayed are the
means (±SEM) from 3 different patients (*p<0.05; **p<0.01,
n=3). B) The immunoblot depicts AKT activation (T308) in two
representative CLL samples stimulated with 19H8 anti-VLA4
mAbs in presence or absence of idelalisib.
(DOC)
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